Page last updated: 2024-08-23

etoposide and estramustine

etoposide has been researched along with estramustine in 54 studies

Research

Studies (54)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.85)	18.7374
1990's	17 (31.48)	18.2507
2000's	30 (55.56)	29.6817
2010's	6 (11.11)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chapman, JD; Elliott, FG; Lakey, WH; Mador, D; McPhee, MS; Meeker, B; Moore, R; Ritchie, B	1
Fujieda, J; Koyanagi, T; Maru, A; Matsuda, H; Matsuno, T; Minami, S; Morita, H; Nagamori, S; Nonomura, K; Shinohara, N	1
Appel, C; Cummings, G; Esper, PS; Flaherty, LE; Hussain, M; Pienta, KJ; Redman, B	1
Pienta, KJ; Redman, BG	1
Atkins, CD	1
Roth, BJ	1
Lehr, JE; Pienta, KJ	1
Lehr, JE; Naik, H; Pienta, KJ	1
Flaherty, L; Katato, K; Varterasian, M	1
Colleoni, M; Graiff, C; Manente, P; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G	1
Bandekar, R; Cease, K; Esper, PS; Naik, H; Pienta, KJ; Redman, BG; Smith, DC; Strawderman, M	1
Pienta, KJ; Smith, DC	2
Alivizatos, G; Aravantinos, G; Bamia, C; Constantinidis, C; Deliveliotis, C; Dimopoulos, C; Dimopoulos, MA; Kastriotis, I; Kostakopoulos, A; Panopoulos, C; Pantazopoulos, D; Zervas, A	1
Dunn, RL; Pienta, KJ; Smith, DC; Strawderman, MS	1
Akaza, H; Tsukamoto, S	1
Arah, IN; Dixon, SC; Figg, WD; Horti, J	1
Esper, P; Pienta, KJ; Redman, B; Smith, DC; Strawderman, M	1
Fuks, Z; Kelly, WK; Lee, H; Leibel, SA; Metz, E; Scher, HI; Schwartz, L; Smart, T; Zelefsky, MJ	1
Hashine, K; Karashima, T; Nakatsuzi, H; Sumiyoshi, Y; Yamashita, Y	1
Ben-Josef, E; Chuba, P; Fontana, J; Han, S; Hussain, M; Mertens, W; Porter, AT	1
Clark, PE; Clark, SB; Dreicer, R; Klein, EA; Levin, HS; Peereboom, DM	1
Crawford, ED; Dakhil, SR; Eisenberger, MA; Fisher, EI; Goodwin, JW; Hussain, MH; Jones, JA; Mills, GM; Pienta, KJ	1
Kamradt, JM; Pienta, KJ	1
Munshi, HG; Pienta, KJ; Smith, DC	1
Hudes, GR; Obasaju, C	1
Akudugu, JM; Bohm, L; Serafin, AM	1
Naito, K	1
Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J	1
Chay, CH; Dunn, RL; Esper, P; Fardig, J; Olson, K; Pienta, KJ; Smith, DC	1
Syed, S	1
Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG	1
Frank, R; Kelly, WK; Reuter, V; Scher, HI; Schwartz, L; Steineck, G	1
Alamanis, C; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Giannopoulos, A; Gika, D; Kiamouris, C; Koutsilieris, M; Zervas, A	1
Hara, N; Kasahara, T; Katagiri, A; Kawasaki, T; Kimura, M; Morishita, H; Nishiyama, T; Saito, K; Saito, T; Sasagawa, T; Takahashi, K; Tanikawa, T; Tomita, Y	1
Du, W; Fontana, J; Hussain, M; Vaishampayan, U	1
Battistel, C; Hartung, R; Kübler, HR; Lehmer, A; Paul, R; Treiber, U; van Randenborgh, H; Wagenpfeil, S; Wutzler, S	1
Abramjuk, C; Jung, K; Krell, HW; Lein, M; Loening, SA; Rothaug, W	1
Bogdanos, J; Dimopoulos, P; Dimopoulos, T; Halapas, A; Karamanolakis, D; Katopodis, H; Koutsilieris, M; Lembessis, P; Milathianakis, C; Papageorgiou, E; Pissimissis, N; Pitulis, N; Sourla, A; Tenta, R	1
Azuma, K; Hashine, K; Karashima, T; Kasahara, K; Miura, N; Nakatsuzi, H; Numata, K; Sumiyoshi, Y	1
Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC	1
Slovin, SF	1
Brown, MA; Logothetis, C; Millikan, RE; Pagliaro, LC; Thall, PF; Wen, S; Williams, D	1
Asbell, SO; Bae, K; Kerlin, KJ; Michalski, JM; Pienta, KJ; Rajan, R; Rosenthal, SA; Sandler, HM; Sobczak, ML	1
Ariu, L; Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Detti, S; Matei, DV; Nolè, F; Rocco, B; Scardino, E; Spitaleri, G; Verweij, F; Zambito, S	1
Allegro, R; Altieri, V; De Grande, G; Falsaperla, M; Melloni, D; Morgia, G; Napoli, M; Serretta, V; Siragusa, A	1
Golshayan, A; Harrer, GW; Hussain, MH; Mills, GM; Smith, DC; Tangen, CM; Thompson, IM; Van Veldhuizen, PJ; Vogelzang, NJ	1
Dobelbower, M; Donavanik, V; Gomella, L; Grignon, D; Hamstra, DA; Hartford, AC; Hunt, D; Jones, CU; Kerlin, KJ; Kim, H; Kuban, DA; Michalski, J; Moughan, J; Pienta, KJ; Rajan, R; Rosenthal, SA; Rotman, M; Sandler, H; Sartor, AO; Seider, M; Shipley, WU; Zeitzer, K	1

Reviews

9 review(s) available for etoposide and estramustine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
New treatment strategies for hormone refractory prostate cancer. Seminars in urology, 1995, Volume: 13, Issue:2 Topics: Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms; Suramin; Vinblastine	1995
[Progress in oral anti-cancer drug therapy for urological cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3 Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Combinations; Estramustine; Etoposide; Female; Flutamide; Humans; Kidney Neoplasms; Male; Prostatic Neoplasms; Tegafur; Uracil; Urinary Bladder Neoplasms	1999
Paclitaxel in the treatment of hormone-refractory prostate cancer. Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 2 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Estramustine; Etoposide; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms	1999
Etoposide in prostate cancer. Expert opinion on pharmacotherapy, 2000, Volume: 1, Issue:2 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms	2000
Paclitaxel and docetaxel in prostate cancer. Hematology/oncology clinics of North America, 2001, Volume: 15, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin	2001
[Chemotherapy for prostate cancers]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine	2002
[Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2003, Volume: 49, Issue:12 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate	2003
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:7 Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Estramustine; Etoposide; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Leuprolide; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Orchiectomy; Osteoblasts; Osteoclasts; Paracrine Communication; Peptides, Cyclic; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Salvage Therapy; Somatostatin; Survival Analysis; Triptorelin Pamoate	2006

Trials

25 trial(s) available for etoposide and estramustine

Article	Year
[Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1995, Volume: 86, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate	1995
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10 Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Estramustine; Etoposide; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Survival Rate	1994
Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. American journal of clinical oncology, 1997, Volume: 20, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Vinblastine; Vinorelbine	1997
A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology, 1997, Volume: 50, Issue:3 Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms; Survival Rate	1997
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured	1997
Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology, 1997, Volume: 50, Issue:5 Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate	1997
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate	1998
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Quality of Life; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome	1999
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:9 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Estramustine; Etoposide; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; Male Urogenital Diseases; Neoadjuvant Therapy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Risk Factors; Treatment Outcome; Vinblastine; Vindesine	2000
Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. International journal of urology : official journal of the Japanese Urological Association, 2000, Volume: 7, Issue:7 Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms	2000
Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology, 2001, Volume: 57, Issue:2 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Estramustine; Etoposide; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Outcome	2001
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). The Prostate, 2001, Mar-01, Volume: 46, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Middle Aged; Nausea; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Venous Thrombosis	2001
Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide. Cancer, 2001, Jun-01, Volume: 91, Issue:11 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Estramustine; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	2001
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-01, Volume: 21, Issue:5 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome	2003
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer, 2003, Jul-15, Volume: 98, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Survival Rate; Treatment Outcome	2003
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial. Cancer, 2003, Nov-15, Volume: 98, Issue:10 Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome	2003
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology, 2004, Volume: 63, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus; Disease-Free Survival; Estramustine; Etoposide; Gastrointestinal Diseases; Gonadotropin-Releasing Hormone; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Orchiectomy; Peptides, Cyclic; Prostatic Neoplasms; Somatostatin; Survival Analysis; Treatment Outcome; Triptorelin Pamoate	2004
Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma. American journal of clinical oncology, 2004, Volume: 27, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Survival Rate	2004
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Clinical genitourinary cancer, 2007, Volume: 5, Issue:5 Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome	2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Journal of the National Cancer Institute, 2007, Nov-07, Volume: 99, Issue:21 Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence Intervals; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Etoposide; Humans; Ketoconazole; Logistic Models; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine	2007
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris International journal of radiation oncology, biology, physics, 2009, Mar-01, Volume: 73, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Paclitaxel; Prostatic Neoplasms; Thromboembolism	2009
Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	2009
Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. Urologia internationalis, 2009, Volume: 83, Issue:4 Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Estramustine; Etoposide; Hospitalization; Humans; Male; Middle Aged; Patient Compliance; Prostatic Neoplasms	2009
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. Urology, 2011, Volume: 77, Issue:5 Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Estramustine; Etoposide; Humans; Injections, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Risk Factors	2011
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. International journal of radiation oncology, biology, physics, 2015, Oct-01, Volume: 93, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Early Termination of Clinical Trials; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors	2015

Other Studies

20 other study(ies) available for etoposide and estramustine

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. European journal of medicinal chemistry, 2010, Volume: 45, Issue:4 Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water	2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Response of the Dunning R3327H prostatic adenocarcinoma to radiation and various chemotherapeutic drugs. Cancer treatment reports, 1982, Volume: 66, Issue:10 Topics: Adenocarcinoma; Animals; Cisplatin; Estramustine; Etoposide; Female; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Vincristine	1982
Effect of flutamide withdrawal on response assessment of estramustine and etoposide for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Flutamide; Humans; Male; Prostatic Neoplasms	1995
Combination chemotherapy in advanced prostate cancer: a silk purse? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms	1994
Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. The Journal of urology, 1993, Volume: 149, Issue:6 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; In Vitro Techniques; Male; Nuclear Matrix; Prostate; Prostatic Neoplasms; Rats; Tumor Cells, Cultured	1993
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Urology, 1996, Volume: 48, Issue:1 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cell Survival; Cells, Cultured; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Rats	1996
Secondary acute myelogenous leukemia following treatment with oral etoposide. American journal of hematology, 1996, Volume: 53, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms	1996
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma. Neoplasma, 1999, Volume: 46, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Estramustine; Etoposide; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Tumor Cells, Cultured; Vinblastine	1999
Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. International journal of radiation oncology, biology, physics, 2001, Mar-01, Volume: 49, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Estramustine; Etoposide; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Protective Agents; Radiotherapy, Conformal; Survival Analysis	2001
Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status. Urological research, 2002, Volume: 30, Issue:5 Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Gene Expression Regulation; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine	2002
Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls. Cancer, 2003, Nov-15, Volume: 98, Issue:10 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome	2003
Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:7-8 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Remission Induction	2002
In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. The Prostate, 2005, Jun-01, Volume: 63, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Drug Synergism; Estramustine; Etoposide; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Male; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids	2005
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estramustine; Etoposide; Humans; Injections, Intraperitoneal; Male; Neoplasm Invasiveness; Neoplasm Transplantation; Piperazines; Prostatic Neoplasms; Pyrimidines; Rats; Time Factors; Tissue Inhibitor of Metalloproteinases	2007
Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. Hinyokika kiyo. Acta urologica Japonica, 2007, Volume: 53, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Etoposide; Humans; Leukopenia; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Thrombocytopenia	2007
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior. Nature clinical practice. Oncology, 2007, Volume: 4, Issue:9 Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion	2007